Alto Neuroscience, Inc.
ANRO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | $0 | -$0 | $0 |
| % Margin | – | – | – | 31% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -4,305.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -4,374.8% |
| EPS Diluted | -2.5 | -1.35 | -1.08 | -0.36 |
| % Growth | -85.2% | -25% | -200% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |